Stay updated on Phase II Anti-PD1 Epigenetic Therapy Clinical Trial
Sign up to get notified when there's something new on the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page.

Latest updates to the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed study criteria and objectives related to a Phase II study of epigenetic therapy for metastatic non-small cell lung cancer, while adding new collaborators and identifiers related to ongoing research.SummaryDifference44%
- Check15 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check22 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check51 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check72 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check79 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Phase II Anti-PD1 Epigenetic Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page.